Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study: HIV Medicine

A.C. Achhra, A. Mocroft, P. Reiss, C. Sabin, L. Ryom, S. de Wit, C.J. Smith, A. d'Arminio Monforte, A. Phillips, R. Weber, J. Lundgren, M.G. Law, Ferran Torres

Research output: Contribution to journalArticleResearchpeer-review

74 Citations (Scopus)

Abstract

Objectives: The aim of the study was to assess the impact of the gain in body mass index (BMI) observed immediately after antiretroviral therapy (ART) initiation on the subsequent risk of cardiovascular disease (CVD) and diabetes. Methods: We analysed data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study. Outcomes were development of (i) CVD (composite of myocardial infarction/stroke/coronary procedure) and (ii) diabetes. The main exposure variable was change in BMI from ART initiation (pre-ART) to 1 year after initiation (continuous variable) in treatment-naïve individuals initiating ART with no history of CVD or diabetes (for respective outcomes). BMI [weight (kg)/(height (m))2] was categorized as underweight (<18.5), normal (18.5-25), overweight (25-30) and obese (>30). Poisson regression models were fitted stratified for each pre-ART BMI category to allow for category-specific estimates of incidence rate ratio (IRR). Models were adjusted for pre-ART BMI and CD4 count, key known risk factors (time-updated where possible) and calendar year. Results: A total of 97 CVD events occurred in 43982 person-years (n=9321) and 125 diabetes events in 43278 person-years (n=9193). In fully adjusted analyses for CVD, the IRR/unit gain in BMI (95% confidence interval) in the first year of ART, by pre-ART BMI category, was: underweight, 0.90 (0.60-1.37); normal, 1.18 (1.05-1.33); overweight, 0.87 (0.70-1.10), and obese, 0.95 (0.71-1.28) (P for interaction=0.04). For diabetes, the IRR/unit gain in BMI was 1.11 (95% confidence interval 1.03 to 1.21), regardless of pre-ART BMI (P for interaction>0.05). Conclusions: Short-term gain in BMI following ART initiation appeared to increase the longer term risk of CVD, but only in those with pre-ART BMI in the normal range. It was also associated with increased risk of diabetes regardless of pre-ART BMI. HIV Medicine © 2016 British HIV Association.
Original languageEnglish
Pages (from-to)255-268
Number of pages14
JournalHIV Medicine
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2016

Keywords

  • Body mass index
  • Cardiovascular diseases
  • Diabetes
  • Highly active antiretroviral therapy
  • HIV
  • Inflammation
  • Myocardial infarction
  • Weight gain
  • antiretrovirus agent
  • anti human immunodeficiency virus agent
  • adult
  • Article
  • body mass
  • cardiac patient
  • cardiovascular disease
  • cardiovascular risk
  • CD4 lymphocyte count
  • cerebrovascular accident
  • cohort analysis
  • diabetes mellitus
  • diabetic patient
  • female
  • heart infarction
  • human
  • Human immunodeficiency virus infection
  • incidence
  • major clinical study
  • male
  • medical history
  • obesity
  • observational study
  • outcome assessment
  • priority journal
  • risk factor
  • sudden cardiac death
  • underweight
  • weight gain
  • Cardiovascular Diseases
  • chemically induced
  • complication
  • HIV Infections
  • middle aged
  • Adult
  • Anti-HIV Agents
  • Body Mass Index
  • Cohort Studies
  • Diabetes Mellitus
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obesity
  • Risk Factors

Fingerprint

Dive into the research topics of 'Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study: HIV Medicine'. Together they form a unique fingerprint.

Cite this